Annamycin. Antineoplastic anthracycline

Drugs of the Future

Volumn 22, Issue 9, 1997, Pages 948-955

  Graul, A ^a   Prous, J ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3' DEAMINO 3' MORPHOLINOOXAUNOMYCIN; AMRUBICIN; ANNAMYCIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DAUNORUBICIN; DOXORUBICIN; GALARUBICIN; IDARUBICIN; LIPOSOME; NEMORUBICIN; PIRARUBICIN; UNCLASSIFIED DRUG; VALRUBICIN;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; DRUG FORMULATION; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NONHUMAN; REVIEW; THROMBOCYTOPENIA; TOXICITY TESTING;

EID: 0030732709     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1997.022.09.423209     Document Type: Review

References (40)

1. Horton, D., Priebe, W. (Ohio State Univ.). 4-Demethoxy-3′-desamino-2′-haloanthracycline and pharmaceutical compsn. containing same. US 4537882.
2. Horton, D., Priebe, W., Varela, O. Synthesis of antitumor-active (7S, 9S) - 4 -demethoxy - 7 - O - (2,6 - dideoxy - 2 - iodo - α - L -mannopyranosyl) adriamycinone: Preparative resolution of a racemic anthracyclinone by alkoxyhalogenation of a glycal. Carbohydr Res 1984, 130: C1-3.
3. Zou, Y., Priebe, W., Perez-Soler, R. (Univ. Texas System). Submicron liposome suspensions obtained from preliposome lyophilizates. WO 9639121.
4. Zou, Y., Priebe, W., Perez-Soler, R. Lyophilized preliposomal formulation of the non-cross-resistant anthracycline annamycin: Effect of surfactant on liposome formation, stability and size. Cancer Chemother Pharmacol 1996, 39: 103-8.
5. Prous J. Antibiotics and alkaloids. In: The Year's Drug News -Therapeutic Targets, 1995 Edition, Prous Science Publishers, Barcelona, 1995, 555-60.
6. Prous Science Trilogy database 1997.
7. Aronex announces preliminary phase I clinical trial results for annamycin. Aronex Pharmaceuticals, Inc. Press Release 1997, March 13.
8. Zou, Y., Priebe, W., Perez-Soler, R. Antitumor activity and biodistribution of annamycin (2′-I-3′-OH-4′-epi-4-demethoxy-doxorubicin), a lipophilic doxorubicin analog, entrapped in multilamellar liposomes. 2nd Liposome Res Days (June 17-19, Leiden) 1992, Abst P20.
9. Perez-Soler, R., Neamati, N., Zou, Y., Schneider, E., Doyle, L.A., Andreeff, M., Priebe, W., Ling, Y.-H. Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide. Int J Cancer 1997, 71: 35-41.
10. Perez-Soler, R., Ling, Y.H., Zou, Y., Priebe, W. Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells. Cancer Chemother Pharmacol 1994, 34: 109-18.
11. Ling, Y.H., Zou, Y., Priebe, W., Perez-Soler, R. Subcellular distribution of annamycin (Ann), a lipophilic non cross-resistance analogue of doxorubicin (Dox) in KB-3-1 and KB-V-1 (MDR) cells. Proc Amer Assoc Cancer Res 1994, 35: Abst 2311.
12. Perez-Soler, R., Ling, Y.H., Zou, Y., Priebe, W. Cellular pharmacology of free and liposome-entrapped annamycin (Ann) in KB/ S and KB/R cells. Proc Amer Assoc Cancer Res 1993, 34: Abst 1929.
13. Ling, Y.-H., Zou, Y., Priebe, W., Perez-Soler, R. Partial circumvention of multi-drug resistance by annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cells. Int J Cancer 1995, 61: 402-8.
14. Perez-Soler, R., Ling, Y.H., Priebe, W. Overcoming of multidrug resistance and enhanced blood-brain barrier permeability with the use of lipophilic anthracyclines. 7th NCI-EORTC Symp New Drugs Cancer Ther (March 17-20, Amsterdam) 1992, Abst 065.
15. Consoli, U., Priebe, W., Ling, Y.-H., Mahadevia, R., Griffin, M., Zhao, S., Perez-Soler, R., Andreeff, M. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: Comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines. Blood 1996, 88: 633-44.
16. Ling, Y.-H., Priebe, W., Yang, L.-Y., Burke, T.G., Pommier, Y., Perez-Soler, R. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes. Cancer Res 1993, 53: 1583-9.
17. cdc2 kinase activity in P388 cells. Proc Amer Assoc Cancer Res 1994, 35: 2312.
18. Ling, Y.H., Priebe, W., Tseng, M.T., Perez-Soler, R. DNA fragmentation and apoptosis induced by doxorubicin (Dox) and its non cross-resistance analog annamycin (Ann) in P388 parent and multidrug resistant (MDR) cells. Proc Amer Assoc Cancer Res 1993, 34: Abst 1734.
19. Perez-Soler, R., Priebe, W. Anthracycline antibiotics with high liposome entrapment: Structural features and biological activity. Cancer Res 1990, 50: 4260-6.
20. Perez-Soler, R., Priebe, W. Formulation and biological studies with liposome-entrapped 2′-iodo-3′-hydroxy-4′-epi-4-demethoxy doxorubicin (annamycin). J Cancer Res Clin Oncol 1990, 116(Suppl., Part A): Abst A5.221.04.
21. Zou, Y., Reddy, S., Ling, Y.H., Priebe, W., Perez-Soler, R. In vivo antitumor activity of the lipophilic anthracycline annamycin (Ann) entrapped in liposomes against KB/MDR human s.c. xenografts, lung Lewis lung carcinoma (LLC), and s.c. M5076 reticulosarcoma. Proc Amer Assoc Cancer Res 1993, 34: Abst 2183.
22. Grossie, B., Wasan, K. Efficacy of a continuous infusion of liposomal annamycin in sarcoma-bearing rats. Proc Amer Assoc Cancer Res 1995, 36: Abst 2363.
23. Zou, Y., Ling, Y.H., Van, N.T., Priebe, W., Perez-Soler, R. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Cancer Res 1994, 54: 1479-84.
24. Zou, Y., Ling, Y.-H., Reddy, S., Priebe, W., Perez-Soler, R. Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes. Int J Cancer 1995, 61: 666-71.
25. Kumi, R.O., Zou, Y., Chow, D.S.-L., Perez-Soler, R. Development and characterization of a liposomal annamycin formulation using polyethylene glycol derivatized lipid. Pharm Res 1995, 12(9, Suppl.): Abst PDD 7274.
26. Kumi, R.O., Zou, Y.-Y., Chow, D.S.-L., Perez-Soler, R. In vitro evaluation of "stealth" and conventional liposomal annamycin formulations. Pharm Res 1996, 13(9, Suppl.): Abst PT 6031.
27. Cassidy, S., Wasan, K.M. Decreases in high density lipoprotein esterified cholesterol content alters the plasma distribution of annamycin (Ann) and nystatin (Nys). Pharm Res 1996, 13(9, Suppl.): Abst PDD 7111.
28. Wasan, K.M., Perez-Soler, R., Morton, R.E. Differences in lipoprotein concentration and composition modify the plasma distribution of free (Ann) and liposomal annamycin (LAnn). Pharm Res 1995, 12(9, Suppl.): Abst PDD 7190.
29. Wasan, K.M., Perez-Soler, R. Distribution of free and liposomal annamycin within human plasma is regulated by plasma triglyceride concentrations but not by lipid transfer protein. J Pharm Sci 1995, 84: 1094-100.
30. Kwong, M., Wasan, K.M. The pharmacokinetics of lipoprotein distribution of liposomal annamycin (L-Ann) in male (M) and female (F) rabbits. Pharm Res 1996, 13(9, Suppl.): Abst PPDM 8140.
31. Zou, Y., Wasan, K.M., Reddy, S., Ling, Y.H., Priebe, W., Perez-Soler, R. Pharmacokinetics and tissue distribution of different liposomal formulations of annamycin in tumor-bearing mice. Proc Amer Assoc Cancer Res 1994, 35: Abst 2534.
32. Zou, Y., Reddy, S., Wu, Q.P., Priebe, W., Perez-Soler, R. Preparation and pharmacokinetics of annamycin entrapped in liposomes. Proc Amer Assoc Cancer Res 1995, 36: Abst 2145.
33. Zou, Y., Priebe, W., Ling, Y.-H., Perez-Soler, R. Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles. Cancer Chemother Pharmacol 1993, 32: 190-6.
34. Zou, Y., Ling, Y.H., Priebe, W., Perez-Soler, R. Pharmacokinetics and organ distribution of 2′-I-3′-OH-4′-epi-4-demethoxydoxorubicin (annamycin) entrapped in multilamellar vesicles. Proc Amer Assoc Cancer Res 1992, 33: Abst 2668.
35. Zou, Y., Hayman, A., Priebe, W., Perez-Soler, R. Quantitative analysis of the lipophilic doxorubicin analogue annamycin in plasma and tissue samples by reversed-phase chromatography. J Pharm Sci 1993, 82: 1151-4.
36. Perez-Soler, R., Zou, Y., Ling, Y.-H., Priebe, W. Preclinical studies with the lipophilic and non cross-resistant anthracycline annamycin (Ann) formulated in a liposomal carrier. Ann Oncol 1994, 5(Suppl. 5): Abst 109.
37. Perez-Soler, R., Brown, T., Priebe, W. Preclinical studies with a lipophilic anthracycline derivative entrapped in liposomes. Proc Amer Assoc Cancer Res 1991, 32: 2267.
38. Perez-Soler, R., Zou, Y., Stephens, C.L., Reddy, S., Priebe, W. Preclinical toxicity of the lipophilic and non-cross resistant anthracycline annamycin incorporated in liposomes. Proc Amer Assoc Cancer Res 1995, 36: Abst 2183.
39. Zou, Y., Priebe, W., Stephens, L.C., Perez-Soler, R. Preclinical toxicity of liposome-incorporated annamycin: Selective bone marrow toxicity with lack of cardiotoxicity. Clin Cancer Res 1995, 1: 1369-74.
40. Booser, D., Esparza-Guerra, L., Zou, Y., Priebe, W., Perez-Soler, R. Liposomal annamycin. Phase I clinical and pharmacological study. Proc Amer Soc Clin Oncol 1997, 16: Abst 762.